All News
English for the Biologically-Challenged (8.4.2023)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week highlights Veterans, Vegetarians and Antenatal Corticosteroids.
Read Article
Rheumatology Journals Rife With Faulty Conflict-of-Interest
More often than not, conflict-of-interest disclosures in three major rheumatology journals didn't match records in the U.S. government's Open Payments database, researchers found.
Read Article
Antenatal Corticosteroids and Serious Infection in Offspring
A claims data study shows that maternal use of antenatal corticosteroids may be associated with an increased risk of serious infection in the offspring's first 12 months.
Read Article
Bifunctional B-cell Targeted Therapy in IgG4-related Disease
A novel B-cell depletion trial, using obexelimab (a bifunctional, monoclonal antibody that binds CD19 and Fc gamma receptor IIb), has shown efficacy and safety in patients with active IgG4-related disease.
Read Article
Tofacitinib in Polymyalgia Rheumatica (EAST PMR Study)
An open-label, uncontrolled pilot trial has shown that JAK signaling is involved in the pathogenesis of PMR and that tofacitinib is as effective as glucocorticoids (GC) in patients with polymyalgia rheumatica (PMR).
Read Article
Pain in the Neck (7.28.2023)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week COVID persists, mortality from misdiagnosis, and cervical pain is more than a pain in the neck.
Read Article
IL-23 Inhibitor Performance in Psoriatic Disease
IL-23 inhibitors are approved for the treatment of psoriasis and psoriatic arthritis; a single center real-world observational study shows three commercially available IL-23 inhibitors have high and similar drug survival and effectiveness in difficult-to-treat psoriasis and PsA.
Read Article
WHO Safety Study of Five TNF Inhibitors
Large scale analysis of adverse events (AEs) in World Health Organization (WHO) VigiAccess database showed no new safety signals associated with long-standing use of five TNFα inhibitors.
Read Article
SGLT2 Inhibitors Reduce Gout Flares and CV Events
A cohort analysis shows that gout patients initiating sodium–glucose cotransporter-2 inhibitors (SGLT2is) had lower serum urate levels and fewer gouty flares requiring emergency department (ED) visits or hospitalizations.
Read Article
Tofactitinib in PsA & RA: Nine Year Safety Data
Tofacitinib is FDA approved for psoriatic arthritis and rheumatoid arthritis, but long term safety outcomes beyond a year are limited. A real-world, post-marketing surveillance of tofacitinib in PsA and RA shows a consistent pattern of safety with no new safety concerns identified.
Read Article
Voclosporin in SLE - Long-Term Safety and Efficacy
The AURORA 2 study evaluated the long-term safety and efficacy of voclosporin lupus nephritis patients and, after three years, demonstrated long term safety and efficacy following the one-year AURORA 1 study.
Read Article
Infectious Risk with B Cell Therapies in Lupus
A UK registry study of moderate to severe systemic lupus erythematosus (SLE) patients showed that treatment with rituximab or belimumab was not associated with a greater risk of serious infection, when compared to standard of care therapy.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Links:
Links:
Links:
Links:
Links:
